专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160279182A1 CVS TRANSPLANTATION FOR TREATMENT OF BACTERIAL VAGINOSIS 审中-公开
标题翻译：用于治疗细菌性血管病的CVS移植
公开(公告)号：US20160279182A1
公开(公告)日：2016-09-29
申请号：US15174540
申请日：2016-06-06
申请人： The Johns Hopkins University
发明人： Laura Ensign , Richard Cone , Justin Hanes
IPC分类号： A61K35/747 , A61K9/00
CPC分类号： A61K35/747 , A61K9/00 , A61K9/0034 , A61K9/0095 , A61K9/19
摘要： Methods and materials for treating bacterial vaginosis (“BV”) are provided. Cervicovaginal secretions (“CVS”) from a woman with vaginal microbiota dominated (>50%) by one of the species of lactobacillus typically found in the human vagina, e.g. Lactobacillus crispatus, L. iners, L. gasseri, L jensenii, is transplanted to women with BV as a method for restoring beneficial vaginal microbial communities and/or increasing resistance to sexually transmitted disease. Efficacy can be enhanced, or the properties of the endogenous CVS improved, through administration of an acidifying agent such as lactic acid. The examples demonstrate the role of healthy CVS in disease resistance, and the effect of pH on CVS properties. The examples also describe the collection and transplantation of healthy beneficial CVS into women at risk for, or after treatment for, BV.
摘要翻译：提供了治疗细菌性阴道病的方法和材料（“BV”）。来自阴道微生物群体的女性的阴道分泌物（“CVS”）由人阴道通常存在的乳酸杆菌种之一（> 50％）占主导地位（> 50％）。将乳酸乳杆菌（Lactobacillus crispatus），L.erers L.，Gasseri，L jensenii移植到具有BV的妇女中，作为恢复有益的阴道微生物群落和/或增加对性传播疾病的抵抗力的方法。通过施用酸性剂如乳酸，可以提高功效或内源性CVS的性质。这些实施例证明了健康CVS在抗病性中的作用以及pH对CVS性质的影响。这些例子还描述了将健康有益的CVS收集和移植到有BV或BV治疗风险的妇女中。

2. 发明申请

US20150297531A1 NANOPARTICLE FORMULATIONS WITH ENHANCED MUCOSAL PENETRATION 有权
标题翻译：具有增强粘膜渗透性的纳米颗粒制剂
公开(公告)号：US20150297531A1
公开(公告)日：2015-10-22
申请号：US14373324
申请日：2013-01-21
申请人： The Johns Hopkins University
发明人： Laura Ensign , Richard Cone , Justin Hanes
IPC分类号： A61K9/51 , A61K31/704 , A61K9/00
CPC分类号： A61K9/5146 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/0048 , A61K9/51 , A61K9/5138 , A61K9/5153 , A61K31/704 , Y10S977/773 , Y10S977/906
摘要： Hypotonic formulations were evaluated for delivering water-soluble drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-penetrating nanoparticles (MPP). Hypotonic formulations markedly increased the rate at which drugs and MPP reached the epithelial surface, including deep into the vaginal folds. Minimally hypotonic formulations, preferably ranging from 20-220 mOsm/kg, provided rapid and uniform delivery of MPP to the entire vaginal surface, with minimal risk of epithelial toxicity. Data also show that there is a higher osmolality in the colon, such that vehicles with an osmolality above that of blood plasma (generally considered isotonic at ˜300 mOsm/kg), still lead to improvements in distribution in the colon due to rapid, osmotically-induced fluid absorption. The range for improved colon distribution with a hypotonic vehicle in the colon is ˜20 mOsm/kg-450 mOsm/kg.
摘要翻译：评价低渗制剂用于递送水溶性药物和用粘膜惰性（即非粘性）粘液穿透纳米颗粒（MPP）进行药物递送。低血糖配方显着增加药物和MPP达到上皮表面的速度，包括深入阴道褶皱。微创低渗制剂优选范围为20-220mOsm / kg，提供MPP快速均匀地输送到整个阴道表面，具有上皮毒性的最小风险。数据还显示，在结肠中存在较高的重量克分子渗透浓度，使得重量摩尔渗透压浓度高于血浆的载体（通常被认为是〜300mOsm / kg的等渗）仍然导致由于快速，渗透性而在结肠中分布的改善吸收液体。在结肠中用低渗媒介物改善结肠分布的范围为〜20mOsm / kg-450mOsm / kg。

3. 发明授权

US11897939B2 Compositions and methods for inhibiting pathogen infection 有权
公开(公告)号：US11897939B2
公开(公告)日：2024-02-13
申请号：US17066874
申请日：2020-10-09
申请人： The University of North Carolina at Chapel Hill , The Johns Hopkins University
发明人： Samuel Lai , Ying-Ying Wang , Arthi Kannan , Kenetta Nunn , Durai Babu Subramani , Richard Cone , Bing Yang , Justin Mccallen
IPC分类号： C07K16/08 , A61P31/22 , C07K16/10 , A61P31/14 , C07K16/12 , A61P11/00 , A61P31/12 , A61K39/00
CPC分类号： C07K16/087 , A61P11/00 , A61P31/12 , A61P31/14 , A61P31/22 , C07K16/10 , C07K16/1027 , C07K16/1214 , A61K2039/505 , A61K2039/544 , C07K2317/13 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/54 , C07K2317/76
摘要： The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

4. 发明授权

US10646434B2 Hypotonic microbicidal formulations and methods of use 有权
公开(公告)号：US10646434B2
公开(公告)日：2020-05-12
申请号：US16123278
申请日：2018-09-06
申请人： The Johns Hopkins University
发明人： Katharina Maisel , Craig W. Hendrix , Laura Ensign , Edward Fuchs , Richard Cone , Justin Hanes
IPC分类号： A61K9/00 , A61K8/90 , A61K47/10 , A61K9/51 , A61K31/09 , A61K31/365 , A61K31/352 , A61K9/06 , A61K31/52 , A61K31/675
摘要： Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.

5. 发明申请

US20180221293A1 MUCUS PENETRATING PARTICLES WITH HIGH MOLECULAR WEIGHT AND DENSE COATINGS 审中-公开
公开(公告)号：US20180221293A1
公开(公告)日：2018-08-09
申请号：US15771961
申请日：2016-10-31
申请人： The Johns Hopkins University
发明人： Justin Hanes , Katharina Maisel , Laura Ensign , Richard Cone
IPC分类号： A61K9/51 , A61K9/00
摘要： Mucus penetrating particles (MPPs) include one or more core polymers, one or more therapeutic, prophylactic and/or diagnostic agents; and one or more surface modifying agents. The surface modifying agents coat the surface of the particle in a sufficient density to enhance the diffusion of the modified nanoparticles throughout the mucosa, relative to equivalent nanoparticles that are not surface modified. Nanoparticles can be sufficiently densely coated with poly(ethylene glycol) (PEG) with a molecular weight of from 10 kD to 40 kD or greater coated with a surface density from about 0.1 to about 100 molecules/100 nm2, preferably from about 0.5 to about 50 molecules/100 nm2, more preferably from about 0.9 to about 45 molecules/100 nm2.

6. 发明申请

US20160317459A1 NANOPARTICLE FORMULATIONS WITH ENHANCED MUCOSAL PENETRATION 有权
公开(公告)号：US20160317459A1
公开(公告)日：2016-11-03
申请号：US15207803
申请日：2016-07-12
申请人： The Johns Hopkins University
发明人： Laura Ensign , Richard Cone , Justin Hanes
IPC分类号： A61K9/51 , A61K31/704 , A61K9/00
CPC分类号： A61K9/5146 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/0048 , A61K9/51 , A61K9/5138 , A61K9/5153 , A61K31/704 , Y10S977/773 , Y10S977/906
摘要： Hypotonic formulations were evaluated for delivering water-soluble drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-penetrating nanoparticles (MPP). Hypotonic formulations markedly increased the rate at which drugs and MPP reached the epithelial surface, including deep into the vaginal folds. Minimally hypotonic formulations, preferably ranging from 20-220 mOsm/kg, provided rapid and uniform delivery of MPP to the entire vaginal surface, with minimal risk of epithelial toxicity. Data also show that there is a higher osmolality in the colon, such that vehicles with an osmolality above that of blood plasma (generally considered isotonic at ˜300 mOsm/kg), still lead to improvements in distribution in the colon due to rapid, osmotically-induced fluid absorption. The range for improved colon distribution with a hypotonic vehicle in the colon is ˜20 mOsm/kg-450 mOsm/kg.

7. 发明授权

US11633350B2 Hypotonic microbicidal formulations and methods of use 有权
公开(公告)号：US11633350B2
公开(公告)日：2023-04-25
申请号：US16717570
申请日：2019-12-17
申请人： The Johns Hopkins University
发明人： Katharina Maisel , Craig W. Hendrix , Laura Ensign , Edward Fuchs , Richard Cone , Justin Hanes
IPC分类号： A61K9/00 , A61K8/90 , A61K9/51 , A61K31/09 , A61K31/365 , A61K47/10 , A61K31/352 , A61K9/06 , A61K31/52 , A61K31/675 , A61K9/08 , A61K8/72
摘要： Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.

8. 发明申请

US20230074691A1 HYPOTONIC HYDROGEL FORMULATIONS FOR ENHANCED TRANSPORT OF ACTIVE AGENTS AT MUCOSAL SURFACES 有权
公开(公告)号：US20230074691A1
公开(公告)日：2023-03-09
申请号：US17898318
申请日：2022-08-29
申请人： The Johns Hopkins University
发明人： Katharina Maisel , Laura Ensign , Justin Hanes , Richard Cone
IPC分类号： A61K9/00 , A61K8/90 , A61K9/51 , A61K31/09 , A61K31/365 , A61K47/10 , A61K31/352 , A61K9/06 , A61K31/52 , A61K31/675
摘要： Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.

9. 发明授权

US10829543B2 Compositions and methods for inhibiting pathogen infection 有权
公开(公告)号：US10829543B2
公开(公告)日：2020-11-10
申请号：US16138643
申请日：2018-09-21
申请人： The University of North Carolina at Chapel Hill , The Johns Hopkins University
发明人： Samuel Lai , Ying-Ying Wang , Arthi Kannan , Kenetta Nunn , Durai Babu Subramani , Richard Cone , Bing Yang , Justin Mccallen
IPC分类号： C07K16/08 , A61P31/12 , C07K16/10 , A61P31/22 , A61P31/14 , C07K16/12 , A61P11/00 , A61K39/00
摘要： The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

10. 发明申请

US20200085733A1 HYPOTONIC HYDROGEL FORMULATIONS FOR ENHANCED TRANSPORT OF ACTIVE AGENTS AT MUCOSAL SURFACES 审中-公开
公开(公告)号：US20200085733A1
公开(公告)日：2020-03-19
申请号：US16684302
申请日：2019-11-14
申请人： The Johns Hopkins University
发明人： Katharina Maisel , Laura Ensign , Justin Hanes , Richard Cone
IPC分类号： A61K9/00 , A61K31/675 , A61K31/52 , A61K9/06 , A61K31/352 , A61K47/10 , A61K31/365 , A61K31/09 , A61K9/51 , A61K8/90
摘要： Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式